News & Analysis on Clinical Trial Services & Contract Research And Development
German pharmaceutical company, Boehringer Ingelheim (BI) and Ark Therapeutics have signed an agreement granting BI exclusive rights to Ark's intellectual property in relation to BI therapies affecting the renin-angiotensin system.
Serono of Switzerland is planning to expand its billion dollar multiple sclerosis franchise with a new version of interferon beta that would do away with the need for injections, reports Phil Taylor.
US researchers have found a compound, TAK-187, is significantly more effective than the current treatment for Chagas disease, a parasitic infection in Central and South America and Mexico, that can infect almost 650,000 people annually, resulting in...
A new generation of cholesterol lowering drugs could be in the offering after a team of scientists identified a key protein that is involved in cholesterol regulation. The discovery could provide alternatives for the 25 million people worldwide that...